Central nervous system resilience to cyclophosphamide: preserved behavior, astrocytes and LGALS3 expression in immunosuppressed mice Authors: Rogério Aires, Alex de Camargo Coque, Lucas Maruchi Delapena Silva, Arila Adorno Scorzafava Gonçalves, Liebert Bernardes Carvalho, Rafael Lopes Correia Tagliaferri, Elizabeth Cristina Perez Hurtado, Eduardo Bondan, José Guilherme Xavier, Maria Martha Bernardi, Rodrigo Augusto Foganholi da Silva Published: 2026 ABSTRACT AbstractBackgroundCyclophosphamide is widely used as an immunosuppressive agent in experimental models. However, its potential effect on central nervous system (CNS) function and behavior may confound studies investigating neuroimmune interactions, interpretation of results, and translational relevance.ObjectivesTo characterize longitudinal behavioral outcomes and CNS-related molecular and histological changes following repeated cyclophosphamide-induced immunosuppression in mice.MethodsAdult male C57BL/6 mice received an intraperitoneal injection of cyclophosphamide (100 mg/kg) for three or four consecutive weeks. Peripheral immunosuppression was assessed by body weight monitoring and leukocyte differential counts. Behavioral performance was evaluated longitudinally using the SHIRPA protocol, open-field test, and tail suspension test (TST). CNS integrity was analyzed through histopathology, GFAP immunohistochemistry, and quantitative PCR analysis of Lgals3 in brain tissue.ResultsCyclophosphamide administration induced a sustained reduction in body weight gain and significant alterations in leukocyte profile, confirming immunosuppression. Behavioral assessment did not demonstrate significant changes, only mild and transient ones, mainly related to muscle strength and subtle sickness-like behavior. No histopathological alterations or astrocytic activation were detected in brain tissue, as GFAP immunoreactivity remained unchanged across experimental groups. Lgals3 gene expression was significantly upregulated in the brains of immunosuppressed animals following both three and four cycles.ConclusionRepeated low-dose cyclophosphamide administration induces effective peripheral immunosuppression without causing overt neuroinflammation or major impairment, indicating CNS resilience under these experimental conditions. The upregulated Lgals3 expression suggests an adaptive neuroimmune response that may contribute to maintaining CNS homeostasis during systemic immune dysregulation. These findings support the use of this immunosuppressive protocol in experimental models targeting CNS infections or neuroimmune mechanisms while minimizing confounding neurotoxic effects.Keywords: Cyclophosphamide, Immunosuppression, Behavioral, Galectin-3, Lgals3 Introduction The immune system is a complex network of cells and tissues within our bodies that work together to defend us against pathogens (such as bacteria, viruses, and parasites) and abnormal cells (such as tumors and transplanted cells), while recognizing the host organism and limiting damage to itself (Nicholson, 2016; Shilts et al., 2022). This system is characterized as a remarkable defense mechanism, providing both innate and adaptive immunity (Sadighi Akha, 2018). Innate immunity, which represents the body's first line of defense, is formed by physical barriers such as the skin, membranes, and mucus, as well as cells such as neutrophils, macrophages, and natural killer cells (Goodarzi et al., 2007; Zhou et al., 2025). On the other hand, adaptive immunity, or acquired immune response, is a comparatively slower process that acts as a highly specific and sophisticated defense mechanism. Unlike the innate immune system, the adaptive immune system is driven by specialized immune cells (mainly T and B cells) to recognize and eliminate specific pathogens, generating a highly specific response with immunological memory (Roy et al., 2022; R. Wang et al., 2024; Marshall et al., 2018) and its correct functioning is crucial for maintaining health and vitality (Calder et al., 2020). The loss of homeostasis in the immune system leads to a failure in the immune response, which can result in various diseases, including hypersensitivity, characterized by excessive and undesirable reactions caused by the dysfunction of the immune system and immunodeficiency conditions (Zhou et al., 2025). In this sense, immunosuppression can be a medical strategy designed in various clinical scenarios (Hussain and Khan, 2022) to modulate or weaken the body's immune system to manage autoimmune diseases (Romano et al., 2019), prevent organ transplant rejection (Duncan, 2005), and reduce inflammation (D. Wang and DuBois, 2015), offering notable benefits in these contexts, but also presenting significant risks and considerations that must be carefully weighed (Florou et al., 2021). Among the various immunosuppressive drugs, cyclophosphamide (Cy) stands out as an antineoplastic agent that reduces leukocyte populations (Brode and Cooke, 2008). This fact means it is used in numerous immunosuppression models in animals to study the pathogenicity of numerous microorganisms (Huyan et al., 2011; Proietti et al., 1998) that may develop anxiety and depression-like behavior as a result of its administration (Zhao et al., 2022; Kitamura et al., 2021), behaviors that may interfere with studies aimed at characterizing the progression of infections that may affect the Central Nervous System. Cyclophosphamide has been associated with neurotoxic effects, particularly under conditions of repeated or high-dose administration. Experimental studies have demonstrated that cyclophosphamide can induce neuroinflammation characterized by increased production of pro-inflammatory cytokines and activation of glial cells. Additionally, cyclophosphamide promotes oxidative stress in brain tissue through increased production of reactive oxygen species (ROS), mitochondrial dysfunction, and disruption of cellular homeostasis, contributing to neuronal damage and functional impairment. Published studies have demonstrated that cyclophosphamide administration promotes an increase in reactive oxygen species (Chen et al., 2024), activation of the inflammatory response in the CNS (Mishra et al., 2022), altered release of neurotransmitters (Onaolapo et al., 2023), and behavioral dysfunction (Mishra et al., 2022). These neurobiological alterations may result in behavioral changes, including anxiety-like behavior, depressive-like symptoms, and reduced locomotor activity, suggesting that cyclophosphamide may directly or indirectly affect CNS function depending on the dosage, duration of exposure, and experimental conditions (Ozatik et al., 2023; Kitamura et al., 2021; Emadi et al., 2009). Repeated administration of cyclophosphamide for three and four consecutive weeks was selected based on previously validated experimental protocols demonstrating that sustained immunosuppression requires cumulative exposure over multiple dosing cycles. Studies have shown that repeated cyclophosphamide administration induces progressive depletion of lymphocytes and establishes stable immunosuppression while minimizing acute toxicity (Lallo and Hirschfeld, 2012; Madondo et al., 2016). Furthermore, longitudinal protocols spanning multiple weeks allow for the evaluation of adaptive physiological and neuroimmune responses, including oxidative stress, neuroinflammation, and behavioral outcomes (Christie et al., 2012; Ozatik et al., 2023; Mishra et al., 2022). This approach provides a reliable and translationally relevant model of systemic immunosuppression. Galectin-3 is a key immunomodulatory lectin expressed in monocytes, macrophages, and glial cells, where it regulates cytokine production and neuroimmune responses (Novak et al., 2012; Srejovic et al., 2020). The role and regulation of Gal-3 expression during differentiation of human monocytes into particular macrophage subsets and their activation remain largely unknown (Novak et al., 2012), although Gal-3 plays an important role in physiological CNS functions (Srejovic et al., 2020). Because they constitute a widely distributed group of proteins, both across different cells and tissues and across several metazoan species, prototypical galectins are characterized by a single carbohydrate recognition domain (CRD), which is also the most numerous subgroup of galectins. However, galectin-3, the only representative of the chimera type, possesses a CRD linked to the N-terminal domain, which allows its oligomerization, resulting in the formation of pentamers (Günther and Galuska, 2023). In addition to playing an essential role in the physiological functions of the CNS, galectin-3 may also be implicated in a variety of neurological disorders. Galectin-3, encoded by the Lgals3 gene, participates in the regulation of neuroinflammatory responses, modulation of microglial activation, promotion of cell survival, regulation of cytokine production, and tissue repair processes following neural injury, and is constitutively expressed in both glial cells and neuronal tissues across different brain regions in normal adults (Yoo et al., 2017; Srejovic et al., 2020; Chaudhary et al., 2022). Furthermore, galectin-3 has been associated with several neurological and neurodegenerative disorders, including Alzheimer's disease, multiple sclerosis, strokes, and traumatic brain injuries, where it contributes to immune signaling, phagocytic activity, and maintenance of CNS homeostasis under pathological conditions (Lee et al., 2025; Srejovic et al., 2020). Thus, this study aimed to characterize longitudinal behavior during cyclophosphamide-induced immunosuppression following repeated doses, and to determine the transcriptional profile of the Lgals3 gene, which encodes the galectin-3 protein involved in neuroimmune regulation, in brain tissue. Material and methods Ethical statements The present study was approved by the Ethics Commission of Paulista University (permit N. 7694091222 CEUA/UNIP). The experiments were conducted in accordance with the National Research Council's Guidelines for the Care and Use of Laboratory Animals, and all efforts were made to minimize the animals' suffering and reduce their number. Animals Forty adult male Black C57BL/6 mice, specific pathogen-free (SPF), aged 3 to 4 weeks and weighing between 17 and 30 g, were obtained from the Center for Development of Experimental Models for Medicine and Biology (CEDEME – UNIFESP) and maintained in the Animal Facility of the Department of Graduate Studies in Environmental and Experimental Pathology at UNIP – Paulista University in São Paulo. Only male animals were used to minimize the potential confounding effects of hormonal fluctuations associated with the estrous cycle, which are known to influence immune responses, neuroinflammatory processes, and behavioral outcomes, thereby increasing experimental variability (Beery and Zucker, 2011; Klein and Flanagan, 2016). The animals were kept for 10 days for acclimatization in microisolators, with five animals per microisolator. They were housed in a temperature-controlled environment at 23 °C ± 1 °C, with 45–55% humidity, and a 12-h light/dark cycle (lights on at 8 a.m.). Animals were fed ad libitum with irradiated, pelleted chow, and water was autoclaved. The 40 animals were divided into four groups: 10 Control, 10 Cy_3 (three weeks), 10 Cy_4 (four weeks), and 10 Sham. The Control group consisted of animals that did not undergo any intervention, whereas the Sham group received weekly injections of sterile PBS. The remaining groups received weekly cyclophosphamide injections for 3 weeks (Cy_3) and 4 weeks (Cy_4), respectively. Induction of immunosuppression by cyclophosphamide Cyclophosphamide (Cy) was administered following the framework established by Lallo and Hirschfeld (2012), with a strategic modification to the dosing schedule. While the original protocol utilized 100 mg/kg twice weekly, we opted for a once-weekly administration of the same dose. This adjustment was implemented to maintain the established therapeutic potency of the 100 mg/kg once weekly dosage while minimizing cumulative toxicity and handling-related stress, ensuring a more sustainable longitudinal observation. Mice received a weekly intraperitoneal dose of 100 mg/kg cyclophosphamide (Cy), totaling 4 doses (Genoxal®, Asta Médica Oncologia, São Paulo, Brazil). For this, Cy was diluted in 0.9% saline solution, and 100 μL was administered intraperitoneally (i.p.) for every 10 g of animal weight. Animals in the control group received only 0.9% saline solution intraperitoneal, as shown in Fig. 1. Timeline. Experimental timeline showing acclimatization, four weekly cycles of cyclophosphamide (100 mg/kg, i.p.), and behavioral assessments (SHIRPA, open field, tail suspension). Peripheral blood smear and scheduled euthanasia were performed after the treatment cycles. Brain samples were collected for HE staining, immunohistochemistry, and gene expression analyses. Legends: C.behavior = basal behavior, Cy = cyclophosphamide, i.p. = intraperitoneal, Cy_1 = first dose of cyclophosphamide, Cy_2 = second dose of cyclophosphamide, Cy_3 = third dose of cyclophosphamide, Cy_4 = fourth dose of cyclophosphamide. The first dose of cyclophosphamide was administered immediately after completion of the protocol evaluation (SHIRPA), which assessed the animals' baseline behavior. The second collection was performed 7 days after administration of the first dose (Cy_2); the third, 7 days after administration of the second dose (Cy_3); and the fourth, 7 days after administration of the third dose. After data collection using the SHIRPA protocol, the animals received the fourth cyclophosphamide (Cy_4) dose. For the Open Field and Tail Suspension behaviors, the analyses were performed over two periods. The first behavioral analysis was performed 7 days after the second dose to assess the treatment effect 14 days after its initiation (Cy_3). The second analysis was conducted immediately after the fourth dose to assess the impact of the treatment 21 days after its initiation (Cy_4). Both were accompanied by euthanasia and sample collection. SHIRPA protocol To provide a behavioral and functional profile of the mice, the SHIRPA protocol was applied weekly as a procedure for longitudinal assessment of the effects of Cy-induced immunosuppression, with some modifications (Rogers et al., 2001). This protocol allowed us to assess the long-term effects of cyclophosphamide-induced immunosuppression on animal behavior. Behaviors were scored to provide a quantitative assessment of each parameter evaluated: motor behavior (tail elevation, negative geotaxis, trunk curvature, limb tone, tremor), muscle strength and tone (wire maneuver, body tonus), sensory function (corneal and righting reflex), neuropsychiatric function (general activity, touch escape, photophobia, toe pinch, touch response, vocalization) and autonomic function (urination, defecation). For scoring, each item was rated using the standard SHIRPA ordinal scale, in which predefined score categories reflect the severity or presence of an abnormality (e.g., normal performance vs. mild, moderate, or marked impairment, depending on the parameter), and the resulting values were recorded for each animal at every weekly session to enable longitudinal comparisons across time and experimental groups (Rogers et al., 2001). The SHIRPA test battery was performed for all groups, with one baseline test and then every seven days until the day of euthanasia. Between tests, the test site was sanitized with 5% alcohol solution. Open-field test The open-field test is used to evaluate sickness behavior induced by Cy (Prut et al., 2003). The device is round, 40 cm in diameter and 30 cm in height, and painted white. The test room was small, dimly lit, and isolated from the experimenter. The locomotion time, rearing frequencies, grooming time (s), grooming frequency, immobility time (s), and immobility frequency were assessed over the period of 5 min. A video camera mounted 100 cm above the arena collected the data for posterior analysis. All apparatus was cleaned with a 5% alcohol/water solution before each trial to eliminate potential olfactory cues from previous animals (Kraeuter et al., 2019). Mice were suspended by the tail using adhesive tape positioned approximately 1 m above the ground, with the ventral surface oriented toward the observer. Tail suspension test (TST) The animals were suspended 1 m above the ground using adhesive tape, with their bellies facing the researcher. All sessions were recorded for 6 min using a digital camera. This test assesses the animal's response to depressive-like behavior associated with immunosuppression. For our study, three factors were considered: latency to the first immobility episode, immobility time (how long the animal remained immobile), and frequency of immobility (how often the animal remained immobile). The apparatus was cleaned with a 5 % alcohol/water solution before placement of the mouse to prevent possible biasing effects from odor cues left by previous mice (Can et al., 2011). Peripheral blood smear To perform a manual cellular differential of the white blood cells after completion of all procedures, a thin blood smear was prepared on a slide (75 mm long, 25 mm wide, 1.35 mm thick) with 50 μL of the heparinized total blood. For each treatment, three blood smears were stained using the Giemsa technique (Laborclin, Paraná, Brazil). The stained slides were examined under an oil-immersion lens using a Nikon eclipse E200 light microscope (Nikon Inc. USA). A trained technician counted and classified at least 100 white blood cells to determine the percentages of each type of leukocyte present: neutrophils, lymphocytes, monocytes, eosinophils, basophils or atypical lymphocytes, band neutrophils and immature granulocytes. Histopathological and immunohistochemical parameters For histopathological and immunohistochemical studies, the right hemisphere of the brain was previously perfused with PBS and fixed in 10% buffered formalin for 72 h. All samples were dehydrated, clarified, embedded in paraffin, sectioned by handheld microtome and stained with hematoxylin-eosin. Immunohistochemical staining was performed using the chain polymer-conjugated staining method (DAKO EnVision System). For this purpose, a rabbit polyclonal anti-GFAP primary antibody (1:50; Z0334, Agilent, Santa Clara, CA, USA) was used, followed by the EnVision + Kit for detection (HRP, Rabbit, DAB+, K4011, Dako/Agilent, Santa Clara, CA, USA). Ten photomicrographs of each slide were analyzed using a 40× objective lens. Morphometric analysis of the immunohistochemically stained sections was performed using the per area index of the Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, Maryland, USA) calibrated with digital color filters so that only positive cells were included and background staining was excluded from the measurement. The index per area represents the proportion of the marked area in relation to the total area of the image, with 0 being the complete absence of marking, and 1 being the total marking of the area (Carvalho et al., 2023). To avoid interference between histological and molecular analyses, the right hemisphere was used for histopathological evaluation, while the left hemisphere was reserved for RNA extraction and gene expression analysis. This approach ensures preservation of tissue morphology for histology and RNA integrity for RT-qPCR, minimizing methodological bias. Lgals3 gene expression Total RNA was isolated from the left hemisphere using the TRIzol® (Thermo Fisher Scientific, Waltham, Massachusetts, USA)/Chloroform/Isopropanol method (Rio et al., 2010). cDNA synthesis was then performed after treatment of the total RNA with DNase I (Invitrogen, Carlsbad, CA, USA), using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions. The Lgals3 gene expression quantification was performed using SYBR Green (Applied Biosystems®, USA) in a QuantStudio® 3 Real-Time PCR (Thermo Fisher Scientific, Waltham, Massachusetts, USA). All reactions were performed in a total volume of 10 μL, containing Syber Green Master Mix 2× (5 μL), 0.4 μM of each primer, 50 ng of cDNA and nuclease-free H2O. The results were analyzed using the ΔΔCt method (Schmittgen and Livak, 2008) and are presented as relative amounts of the target gene using β-actin, (Actb gene) glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and 18S ribosomal RNA (18S) as internal reference genes. Normalization of target gene expression was performed using the geometric mean of the Ct values obtained from the three housekeeping genes (Actb, Gapdh, and 18S), in order to increase the reliability and stability of gene expression analysis. All reactions were performed in triplicate, and the mean Ct values were used for subsequent analysis. The primer sequence and PCR conditions are shown in Table 1. Table 1Expression primers sequences and PCR cycle conditions.Table 1Gene (ID)PrimerSequence - 5′- 3′Reaction conditionsProductLgals3 (16854)ForwardAAC CAC GCC ATG ATC TAA GC95 °C - 15s; 65 °C - 30s; 72 °C - 30s264ReverseCAC TTG CCT AGC AGT CAC GARn 18s (19791)ForwardCGC GGT TCT ATT TTG TTG GT95 °C - 15s; 60 °C - 30s; 72 °C - 30s179ReverseTCG TCT TCG AAA CTC CGA CTb-actina (11461)ForwardTCT TGG GTA TGG AAT CCT GTG95 °C - 15s; 58 °C - 30s; 72 °C - 30s82ReverseAGG TCT TTA CGG ATG TCA ACGGapdh (14433)ForwardCCG CAG CGA GGA GTT TCT C95 °C - 15s; 63 °C - 30s; 72 °C - 30s530ReverseGAG CTA AGC TCA GGC TGT TCC A Expression primers sequences and PCR cycle conditions. Statistical analysis All statistical analyses were performed using the GraphPad Prism software (version 10.1; GraphPad Software Inc., San Diego, CA, USA). Data normality was assessed using the Shapiro–Wilk test. Results were expressed as mean ± standard error of the mean (SEM) or standard deviation (SD), as appropriate. Comparisons among multiple groups (Control, Sham, Cy_3, and Cy_4) were performed using one-way ANOVA followed by Sidak's or Tukey's post hoc tests. Comparisons between two groups were performed using Student's unpaired t-test. Longitudinal data were analyzed using repeated-measures ANOVA when appropriate. Gene expression analysis was performed using the comparative Ct method (2ˆ−ΔΔCt), with normalization based on the geometric mean of the housekeeping genes β-actin (Actb), Gapdh, and 18S ribosomal RNA (Schmittgen and Livak, 2008). Histopathological and immunohistochemical data were analyzed using densitometric measurements and compared using one-way ANOVA followed by appropriate post hoc tests. A p-value <0.05 was considered statistically significant. Results Characterization of immunosuppression and its impact on the animal's overall behavioral state The results presented in Fig. 2 demonstrate that immunosuppression induced by cyclophosphamide (Cy) administration compromised the body weight gain of immunosuppressed animals from the first week onwards, maintaining this effect until the end of treatment, when compared to animals in the Sham group (p < 0.0001) that received only the vehicle (sterile PBS buffer) and the Control group (p < 0.0001). On the other hand, the comparison between the Control and Sham groups did not indicate significant differences in body weight gain until the third week (Cy_3), with a slight impairment in body weight gain in the fourth week of treatment (Cy_4) (Fig. 2a). Additionally, the total leukocyte counts on the blood smear revealed that immunosuppression promoted a significant reduction in the lymphocyte population (Fig. 2b) and an increase in the neutrophil population (Fig. 2c) in the third week of treatment (Cy_3). Additionally, qualitative analysis of peripheral blood smears confirmed the leukocyte profile changes observed in the quantitative analysis, showing a predominance of granulocytes and a reduction in lymphocyte frequency in cyclophosphamide-treated animals compared to the Control and Sham groups (Fig. 2d). Characterization of immunosuppression caused by cyclophosphamide. Effect of immunosuppression induced by weekly administration of i.p. Cyclophosphamide (Cy) at a dose of 100 mg/kg on body weight gain (a). Graphical representation of peripheral blood total leukocyte counts, lymphocyte (b) and neutrophil (c) populations using the blood smear technique. Representative photographs of the morphology of blood cells from animals treated with cyclophosphamide for 3 weeks, obtained by light microscopy at 40× magnification (d). Granulocytes predominate (yellow arrows), with occasional immature cells (black arrow) and monocytes (white arrow). Isolated lymphocytes (red arrow) are eventually observed. Giemsa, 100× objective (d). Data represents the mean ± standard error of the mean of 10 animals for body weight gain and 5 animals for blood smear, except for the Control group (n = 4) due to the technical exclusion criteria of one sample during slide quality assessment. For body weight gain (a): ****p < 0.0001 in relation to the Control group and ****p < 0.0001 in relation to the Sham group. For blood smear (b, c) ****p < 0.0001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Characterization of behavioral and molecular parameters after cyclophosphamide-induced immunosuppression SHIRPA protocol The SHIRPA protocol was performed to characterize the behavioral phenotype of mice subjected to immunosuppression throughout the protocol, receiving weekly cyclophosphamide doses. Motor activity, muscle strength and tone, as well as sensory, neuropsychiatric, and autonomic functions were assessed weekly. The results obtained are presented in Table 2 and revealed a few differences in the parameters evaluated between the groups. Regarding the parameters evaluated that assessed motor activity, it was observed that immunosuppression promoted a significant reduction in the tail-lifting parameter only in the second and last (fourth) week after the start of immunosuppression, compared to the Sham group. For the strength and muscle tone parameters, our results showed that immunosuppressed animals had a significant reduction in the wire maneuver score compared to the other groups across all sessions, indicating reduced muscle strength. For Sensory Function, only the Ocular Reflex decreased in the last week, after the fourth dose of cyclophosphamide, in the immunosuppressed animals compared to the Control and Sham groups. Regarding Neuropsychiatric Function, a reduction in general activity was observed in the group of immunosuppressed animals compared only to the Sham group and in vocalization compared to the Control and Sham groups in the evaluation that was carried out before the start of cyclophosphamide administration, with no significant differences being observed in the parameters related to Autonomic Function throughout the experimental period. Table 2SHIRPA protocol.Table 2ParameterArrivalStatistic1°. weekStatistic2°. weekStatistic3°. weekStatistic4°. weekStatisticMotor ActivityControlShamCyControlShamCyControlShamCyControlShamCyControlShamCyTail elevation3.7 ± 03.7 ± 03.9 ± 0#4.0 ± 04.0 ± 03.9 ± 0#3.8 ± 0.13.7 ± 0.24.2 ± 0.1*F = 3.5,P = 0.0444.0 ± 04.0 ± 03.7 ± 0.2F+2.25,p = 0.134.0 ± 0.14.0 ± 0.13.7 ± 0.2*F = 3.80,p = 0.04Negative geotaxis2.6 ± 03.0 ± 02.6 ± 0#3.0 ± 0.73.0 ± 0.74.2 ± 0.5F = 0.17,P = 0.333.4 ± 0.73.0 ± 0.72.5 ± 0.7F = 0.42,P = 0.663.0 ± 0.73.0 ± 0.73.7 ± 0.7F = 0.33,p = 0.723.4 ± 0.73.0 ± 0.72.5 ± 0.7F = 0.33,p = 0.72Trunk curl1.0 ± 01.2 ± 00.8 ± 0#1.0 ± 01.0 ± 01.1 ± 0.2F = 0.25,P = 0.781.0 ± 01.0 ± 00.9 ± 0.1F = 1.0,P = 0.381.0 ± 01.0 ± 01.0 ± 0#1.0 ± 01.0 ± 01.0 ± 0#Limb tone1.3 ± 01.2 ± 01.1 ± 0#1.2 ± 0.21.0 ± 01.0 ± 0.8F = 0.06,P = 0.941.0 ± 01.0 ± 01.0 ± 0.2F = 1.0,P = 0.381.0 ± 01.0 ± 01.0 ± 0#1.0 ± 01.0 ± 01.0 ± 0#Tremor2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 01.6 ± 0.22F = 3.31,P = 0.0512.0 ± 02.0 ± 01.8 ± 0.2F = 1.0,P = 0.382.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 02.0 ± 0# Muscle Strength and ToneWire maneuver2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 01.5 ± 0.2**F = 6.3,P = 0.0044.0 ± 04.2 ± 0.13.7 ± 0.2F+6.25,P = 0.004*4.0 ± 04.2 ± 0.13.7 ± 0.2F = 3.8,P = 0.004*4.0 ± 04.2 ± 0.13.7 ± 0.2*F = 6.3,P = 0.04Body tonus1.4 ± 01.5 ± 01.4 ± 0#1.4 ± 0.21.5 ± 0.21.4 ± 0.2F = 0.08,P = 0.921.4 ± 0.21.4 ± 0.12.0 ± 0F = 7.20,p = 0.003**2.0 ± 0.41.5 ± 0.21.2 ± 0.2F = 2.04,P = 0.152.0 ± 0.41.5 ± 0.21.6 ± 0.2F = 0.88,P = 0.43 Sensory FunctionCorneal reflex2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 02.0 ± 0#2.0 ± 02.0 ± 01.5 ± 0.2**F = 6.25,P = 0.006Righting reflex5.0 ± 05.0 ± 05.0 ± 0#5.0 ± 05.0 ± 0.55.0 ± 0#5.0 ± 05.0 ± 05.0 ± 0.5F = 0.42,P = 0.665.0 ± 05.0 ± 05.0 ± 0#5.0 ± 05.0 ± 05.0 ± 0# Neuropsychiatric FuncionGeneral activty4.0 ± 04.0 ± 03.9 ± 0#4.0 ± 04.0 ± 03.9 ± 0#3.8 ± 0.13.7 ± 0.24.2 ± 0.1*F = 3.5,P = 0.0444.0 ± 04.0 ± 03.7 ± 0.2F = 2.25,P = 0.124.0 ± 04.2 ± 0.13.7 ± 0.2F = 2.25,P = 0.12Touch scape1.0 ± 01.2 ± 01.3 ± 0#1.0 ± 01.0 ± 01.0 ± 0.2F = 1.0,P = 0.381.0 ± 01.0 ± 00.9 ± 0.1F = 1.0,P = 0.381.0 ± 01.0 ± 01.0 ± 0#1.0 ± 01.0 ± 01.0 ± 0#Photophobia003.5 ± 0#001.0 ± 0.7#000#000#000#Toe pinch5.0 ± 04.6 ± 05.0 ± 0#5.0 ± 04.6 ± 05.0 ± 0#5.0 ± 04.6 ± 0.24.5 ± 0.5F = 0.72,P = 0.495.0 ± 04.6 ± 0.24.5 ± 0.5F = 0.72,P = 0.495.0 ± 04.6 ± 0.24.5 ± 0.5F = 0.72,P = 0.49Toe response4.4 ± 04.5 ± 04.4 ± 0#4.4 ± 0.24.5 ± 0.24.4 ± 0.2F = 0.08,P = 0.924.4 ± 0.43.6 ± 0.44.2 ± 0.5F = 0.91,P = 0.414.2 ± 0.24.0 ± 03.7 ± 0.4F = 0.90,P = 0.404.5 ± 0.24.0 ± 04.3 ± 0.5F = 0.66,P = 0.53Vocalization2.0 ± 01.0 ± 03.0 ± 0.7**F = 6.12,P = 0.0062.0 ± 0.72.0 ± 0.81.1 ± 0.7F = 0.50,P = 0.611.0 ± 0.71.0 ± 01.0 ± 0#1.5 ± 0.800#1.5 ± 0.700# Autonomic FunctionUrination1,3 ± 00.9 ± 01.7 ± 0#1,1 ± 0.40.9 ± 0.21.7 ± 0.5F = 1.15,P = 0.330.9 ± 0.10.9 ± 0.10.5 ± 0.2F = 2.67,P = 0.091.4 ± 0.50.7 ± 0.20.7 ± 0.3F = 1.29,P = 0.291.5 ± 0.50.5 ± 0.21.5 ± 0.6F = 1.54,P = 0.24Defecation3.2 ± 02.0 ± 02.5 ± 0#1.5 ± 0.52.6 ± 0.52.0 ± 0.5F = 1.21,P = 0.310.9 ± 0.22.3 ± 0.41.4 ± 0.6F = 2.70,P = 0.092.7 ± 0.52.3 ± 0.52.1 ± 0.5F = 0.37,P = 0.692.1 ± 0.33.4 ± 0.51.8 ± 0.6F = 3.10,P = 0.06 SHIRPA protocol. Open field test Evaluation of locomotor and exploratory behavior over 5 min showed that, in the third week of treatment, the administration of cyclophosphamide significantly reduced only the grooming time (Fig. 3c), with no differences being observed for the other parameters evaluated: locomotion time (Fig. 3a), frequency of rearing (Fig. 3b), grooming frequency (Fig. 3d), and frequency and time of immobility (Fig. 3e and f). Regarding the animals in the group that received four doses of cyclophosphamide, the results were similar to those presented for the animals that received three doses (Fig. 3g–l). Immunosuppressed animals that received 4 doses of cyclophosphamide (Cy_4) showed a significant reduction in grooming time compared to the Control group (p < 0.01). An increase in immobility frequency in animals that received four doses of cyclophosphamide (Cy_4) compared to the Control group (p < 0.05). The graphical representation of the comparison between the animals that received three doses (Cy_3) with the animals that received four doses (Cy_4) showed a difference only in the immobility time, with the immobility time of the animals in the Cy_4 group being shorter than that of the animals in the Cy_3 group (Fig. 4e), with no significant differences being observed for the other parameters (Fig. 4a–d, f). Immunosuppressed animals that received four doses of cyclophosphamide (Cy_4) showed a significantly shorter immobility time compared to the animals that received three doses (Cy_3) (p < 0.01). Effect of cyclophosphamide induction of immunosuppression on locomotor activity. The sickness-like behavior of control animals (Control and Sham) and animals that received 3 (Cy_3) or 4 (Cy_4) weekly i.p. cyclophosphamide doses at 100 mg/kg was evaluated using the open field as a behavioral test. The parameters assessed were Locomotion time (a, g), Rearing frequency (b, h), Grooming time (c, i), Grooming frequency (d, j), Immobility time (e, k) and Immobility frequency (f, l) in the Cy_3 and Cy_4 periods. The results represent the mean ± SEM of 10 independent animals. One-way ANOVA was followed by Sidak's multiple-comparison test. *p < 0.05, **p < 0.01 in relation to the control group. Comparison of locomotor activity of immunosuppressed animals in the Cy3 versus Cy4 periods. Comparison between the locomotor activity of animals immunosuppressed by weekly administration of cyclophosphamide that received 3 (Cy_3) and 4 (Cy_4) i.p. doses at a dosage of 100 mg/kg evaluated in the open field. The parameters evaluated were Locomotion time (a), Rearing frequency (b), Grooming time (c), Grooming frequency (d), Immobility time (e) and Immobility frequency (f). The results represent the mean ± SEM of 10 independent animals. **p < 0.01 in relation to the group Cy_3, Student t-test. Tail suspension test To test the effects of cyclophosphamide administration on depressive-like behavior, the animals were subjected to the tail suspension test and the results were presented in Fig. 5. Our results revealed that of the parameters evaluated, only the immobility time of the animals that received 4 doses of cyclophosphamide showed a significant reduction in relation to the control groups (Control and Sham) (Fig. 5d), with no significant differences being observed for latency to first immobility (Fig. 5a and b), immobility time of the animals that received 3 doses of cyclophosphamide (Fig. 5c) and for the frequency of immobility (Fig. 5e and f). However, when we compared only the Cy_3 and Cy_4 groups of animals that received cyclophosphamide, it was possible to observe a longer latency time for first immobility (Fig. 5g), accompanied by a shorter immobility time (Fig. 5h) and an increase in the frequency of immobility (Fig. 5i) in the group of animals that received 4 doses of cyclophosphamide. Effect of immunosuppression induction by cyclophosphamide on sickness-like behavior. The sickness-like behavior of control animals (Control and Sham) and animals that received 3 (Cy_3) or 4 (Cy_4) doses of weekly i.p. cyclophosphamide at a dose of 100 mg/kg was evaluated using the tail suspension test, with the parameters of Latency to first immobility (a, b), Immobility Time (c, d) and Immobility Frequency (e, f) being evaluated. Comparison between the parameters of Latency to first immobility (g), Immobility Time (h), and Immobility Frequency (i) of immunosuppressed animals that received 3 (Cy_3) and 4 (Cy_4) doses of cyclophosphamide. The results represent the mean ± SEM of 10 independent animals. For the different groups (Control, Sham, Cy_3, or Cy_4), the test used was a one-way ANOVA followed by Tukey's multiple comparisons test. **p < 0.01 in relation to the Control group. For the comparison between the Cy_3 versus Cy_4 groups.**p < 0.01, Student's test, ***p < 0.001, ****p < 0.0001. Histological and molecular characterization of CNS inflammatory response Descriptive microscopic analyses of histological sections of HE-stained brain tissue from immunosuppressed animals that received 3 (Cy_3) or 4 (Cy_4) doses of cyclophosphamide revealed no significant histopathological changes when compared to the Control and Sham groups (Fig. 6a and b). Additionally, to evaluate the effects of immunosuppression on the CNS, immunoreactivity for GFAP was evaluated in the brain tissue. Representative GFAP immunostaining images showed no evident qualitative differences between groups (Fig. 6c and d). Quantitative densitometric analysis further confirmed that GFAP expression levels were not significantly altered in immunosuppressed animals compared to the Control and Sham groups (Fig. 6e and f). In parallel, since the Galectin 3 protein is related to the immune system and neuroinflammation, the expression of the Lgals3 gene was evaluated in the tissue by qPCR. The results obtained showed that for the brain tissue, the administration of cyclophosphamide promoted an upregulation of the expression of the Lgals3 gene both for the animals that received 3 (Fig. 6g) and 4 doses (Fig. 6h) of cyclophosphamide. Impact of Cy-induced immunosuppression on the activation of the inflammatory response in the CNS. Representative photomicrographs of the effect of immunosuppression induced by the administration of Cyclophosphamide (i.p. - 100 mg/kg) in brain tissue stained by the Hematoxylin-Eosin (H.E) technique of the experimental periods Cy_3 (a) and Cy_4 (b) from the Control (a = 20X and b = 40x), Sham (c = 20X and d = 40x) and Cy (e = 20X and f = 40x) groups. Representative photomicrographs of GFAP immunostaining of the Control, Sham and Cy_3 (c) and Cy_4 (d) groups. Graphical representation of the immunoreactivity of the Cy_3 (e) and Cy_4 (f) groups using Image-Pro Plus 6.0 software. For gene expression analysis, total RNA was extracted using the TRIzol®/Chloroform/Isopropanol method, followed by reverse transcription of 2000 ng of total RNA per 1 U of reverse transcriptase enzyme. Then, the quantification of the transcripts of the gene encoding the Galectin-3 (Lgals3) protein was evaluated in immunosuppressed mice: Cy_3 (g) and Cy_4 (h). The Gapdh, Actb, and 18S genes were used as normalizers. The results were calculated using the (2−ΔCt) method and represent the mean ± standard deviation of 10 independent animals performed in technical duplicate. One-way ANOVA followed by the Tukey multiple comparison test. Black asterisk represents the statistical difference in relation to the Control group and the red asterisk represents the statistical difference in relation to the Sham group. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Discussion Cyclophosphamide-induced immunosuppression is widely used in experimental models designed to investigate the pathophysiology of opportunistic infections and host–pathogen interactions (Resendiz-Sharpe et al., 2022). However, the potential behavioral and neurobiological effects of this drug may represent an important confounding factor when interpreting results in studies involving the central nervous system (CNS). In this context, the present study aimed to characterize behavioral, histological and molecular changes associated with repeated cyclophosphamide-induced immunosuppression in mice. In this sense, the immunosuppressive effect of cyclophosphamide is well characterized and, in experimental murine models, it confers an increased risk of infections due to impaired immune responses caused by leukocyte depletion, particularly affecting lymphocyte subpopulations (Ahlmann and Hempel, 2016; Taniura et al., 2020; Madondo et al., 2016; Valdoleiros et al., 2021). In agreement with these reports, our results demonstrated a marked reduction in lymphocyte populations following cyclophosphamide administration, considering the percentage of this population in control animals, including the sham group. Interestingly, although previous studies have reported a decrease in neutrophil populations after cyclophosphamide treatment (Corrier et al., 1979; Moura et al., 2019), our results showed a significant increase in neutrophils. This difference may be related to variations in dose and administration frequency. Many experimental protocols employ higher cumulative doses of cyclophosphamide (often around 200 mg/kg/day) (Brode and Cooke, 2008), whereas in the present study we adopted a weekly administration of 100 mg/kg in order to maintain sustained immunosuppression while minimizing acute toxicity. Since the pharmacokinetic and immunomodulatory effects of cyclophosphamide are strongly dependent on dose and duration of exposure (Ozatik et al., 2023), this protocol likely produced a milder but sustained immunosuppressive state (Marumo et al., 2022; Mori et al., 2016). Body weight reduction is another well-described consequence of systemic immunosuppression and cytotoxic chemotherapy, frequently associated with reduced food intake and systemic metabolic stress (Suryaprasad and Stone, 2008). Our findings are consistent with these observations, as mice treated with cyclophosphamide showed reduced body weight gain throughout the experimental period. In addition, previous studies have demonstrated that depressive-like states may also contribute to weight loss through decreased food intake (Iñiguez et al., 2018; Powell et al., 2012; Prut and Belzung, 2003). The behavioral profile of immunosuppressed animals was evaluated using multiple behavioral paradigms. Overall, behavioral alterations observed in our study were mild and transient. Although most SHIRPA parameters remained unchanged, indicators related to muscle strength and motor function were modestly affected, particularly the wire maneuver test, which showed reduced scores across several evaluation sessions. The reduction in wire maneuver performance suggests possible alterations in muscular strength during immunosuppression. Previous studies have reported that cyclophosphamide can interfere with muscle regeneration and myoblast survival, potentially affecting muscular function (Vilquin et al., 1995). Nevertheless, the magnitude of these changes in our study was limited and did not translate into generalized motor impairment. Regarding depressive-like or sickness-related behaviors, subtle differences were observed in the tail suspension test. Animals exposed to four cycles of cyclophosphamide exhibited increased immobility frequency compared with animals treated for three weeks. Although the tail suspension test is widely used as an experimental model for depressive-like behavior (Powell et al., 2012), the behavioral alterations observed in the present study were modest and likely reflect mild sickness-related responses rather than a clear depressive phenotype. Cyclophosphamide has been reported to induce neurotoxicity characterized by neuroinflammation, oxidative stress and behavioral alterations (Mishra et al., 2022; Ozatik et al., 2023). However, in contrast to these reports, our histological and immunohistochemical analyses did not reveal significant astrocytic activation, as GFAP expression remained unchanged across the experimental groups. This finding suggests that astroglial activation is not an inevitable consequence of cyclophosphamide exposure. Indeed, previous studies indicate that the neurobiological consequences of cyclophosphamide depend strongly on dosage, frequency, and cumulative exposure (Marumo et al., 2022; Onaolapo et al., 2023; Ozatik et al., 2023). Moderate or chronic immunosuppressive protocols may therefore preserve CNS homeostasis despite systemic immune alterations. In addition to histological evaluation, we analyzed the expression of the Lgals3 gene, which encodes the immunomodulatory lectin Galectin-3. This protein plays important roles in the regulation of inflammatory responses and neuroimmune signaling in the CNS (Srejovic et al., 2020). Our results demonstrated that cyclophosphamide treatment induced an upregulation of Lgals3 expression in brain tissue. Galectin-3 has been associated with both pro- and anti-inflammatory functions depending on the biological context (Breuilh et al., 2007). In the CNS, this molecule can participate in microglial activation, immune signaling and tissue repair processes (Srejovic et al., 2020). Therefore, the increased expression of Lgals3 observed in our model may represent an adaptive neuroimmune response aimed at maintaining tissue homeostasis during systemic immunosuppression. Overall, the present findings demonstrate that repeated administration of cyclophosphamide effectively induces peripheral immunosuppression while producing only mild behavioral alterations and no major histological signs of neuroinflammation in the brain. The observed increase in Lgals3 expression suggests the activation of compensatory neuroimmune mechanisms that may contribute to maintaining CNS stability under systemic immune stress. These results support the use of this experimental immunosuppression protocol in studies investigating CNS infections or neuroimmune interactions while minimizing potential confounding neurotoxic effects. Conclusion The present study demonstrates that repeated low-dose cyclophosphamide administration induces a clear and sustained state of peripheral immunosuppression, characterized by impaired body weight gain and alterations in leukocyte profiles, without promoting neuroinflammation or major dysfunction in adult C57BL/6 mice. Behavioral assessments revealed only transient alterations, mainly related to reduced muscle strength and mild sickness-like behavior. Importantly, cyclophosphamide-induced immunosuppression did not result in detectable histopathological changes in brain tissue nor in astrocytic activation, as indicated by unchanged GFAP immunoreactivity across experimental time points. These findings suggest that central nervous system integrity remains preserved despite systemic immune alterations. Interestingly, despite the absence of classical neuroinflammatory markers, cyclophosphamide administration promoted an upregulation of Lgals3 gene expression in brain tissue. This response may reflect an adaptive neuroimmune mechanism aimed at maintaining CNS homeostasis during systemic immunological stress. Taken together, these findings suggest that galectin-3 signaling may contribute to preserving neural integrity and limiting neuroinflammatory responses during prolonged immunosuppression. Therefore, this experimental protocol represents a reliable model of systemic immunosuppression that minimizes confounding neurotoxic effects in studies investigating CNS infections and neuroimmune interactions. Limitations Some limitations of this study should be acknowledged. First, only male animals were used, which limits the extrapolation of the findings to females, given the known influence of sex hormones on immune responses and neuroinflammatory processes. Second, although behavioral, histological, and molecular analyses were performed, the study focused on a limited number of neuroinflammatory markers, particularly GFAP and Lgals3, which may not fully capture the complexity of CNS immune responses. Additionally, the experimental design evaluated only two durations of immunosuppression (three and four weeks), and longer exposure periods could reveal different neurobiological outcomes. Finally, although behavioral alterations were assessed using validated paradigms, more specific cognitive tests could further clarify possible subtle effects of cyclophosphamide on CNS function. Sources of funding The authors are grateful to National Council for Scientific and Technological Development - CNPq for Research Productivity Grants - PQ (RAFS - Process: 301498/2022-9) and CAPES. CRediT authorship contribution statement Rogério Aires: Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. Alex de Camargo Coque: Data curation, Formal analysis, Investigation. Lucas Maruchi Delapena Silva: Investigation, Methodology. Arila Adorno Scorzafava Gonçalves: Investigation, Methodology. Liebert Bernardes Carvalho: Formal analysis, Validation. Rafael Lopes Correia Tagliaferri: Data curation, Visualization. Elizabeth Cristina Perez Hurtado: Investigation, Resources. Eduardo Bondan: Data curation, Investigation, Visualization. José Guilherme Xavier: Investigation, Resources. Maria Martha Bernardi: Investigation, Supervision. Rodrigo Augusto Foganholi da Silva: Conceptualization, Data curation, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing. Declaration of competing interest All authors declare no conflict of interest. Acknowledgements The authors express their gratitude to Prof. Dr. Marcelo Valim (UNIFESP/EPM), all staff researchers, and the laboratory technicians for their support for this study. Funding from CNPq and CAPES was also essential. Abbreviations Central Nervous System Carbohydrate Recognition Domain Cyclophosphamide Galectin-3 Glial fibrillary acidic protein Ionized calcium-binding adapter molecule 1 Gene Galectin-3 Neuronal Nuclear Antigen Phosphate-buffered saline Reactive Oxygen Species Standard Error of Mean Standardized Humanized Investigation of Reflexes and Physiological Abnormalities Tail suspension test Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.